Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $25.67

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have been given an average recommendation of "Buy" by the eight research firms that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $25.67.

Several brokerages have commented on ATXS. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Thursday, February 27th. Oppenheimer raised their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a research note on Thursday, November 14th. Citizens Jmp raised shares of Astria Therapeutics to a "strong-buy" rating in a research note on Friday, January 31st. Finally, JMP Securities initiated coverage on Astria Therapeutics in a research report on Friday, January 31st. They issued an "outperform" rating and a $26.00 target price for the company.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ATXS. KLP Kapitalforvaltning AS acquired a new stake in Astria Therapeutics during the fourth quarter valued at $41,000. Tower Research Capital LLC TRC lifted its holdings in shares of Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after buying an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Astria Therapeutics in the 4th quarter valued at approximately $50,000. Virtus ETF Advisers LLC acquired a new position in Astria Therapeutics in the fourth quarter worth approximately $65,000. Finally, Teacher Retirement System of Texas bought a new position in Astria Therapeutics during the fourth quarter valued at approximately $91,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Astria Therapeutics Price Performance

Shares of ATXS traded down $0.23 during trading hours on Tuesday, hitting $6.19. 228,635 shares of the company were exchanged, compared to its average volume of 263,324. The firm has a fifty day simple moving average of $7.44 and a 200-day simple moving average of $9.76. The company has a market capitalization of $349.33 million, a PE ratio of -2.96 and a beta of 0.69. Astria Therapeutics has a one year low of $5.84 and a one year high of $16.90.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.